392 related articles for article (PubMed ID: 11156402)
41. Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model.
Pilon-Thomas S; Li W; Briggs JJ; Djeu J; Mulé JJ; Riker AI
J Immunother; 2006; 29(4):381-7. PubMed ID: 16799333
[TBL] [Abstract][Full Text] [Related]
42. Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4(+) T cell-dependent mechanism.
Steitz J; Brück J; Knop J; Tüting T
Gene Ther; 2001 Aug; 8(16):1255-63. PubMed ID: 11509959
[TBL] [Abstract][Full Text] [Related]
43. [Enhanced translational efficacy of internal ribosomal entry site-mediated mRNA in dendritic cells contributes to efficient induction of antitumor immunity].
Tan XH; Wan YH
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):399-403. PubMed ID: 17456382
[TBL] [Abstract][Full Text] [Related]
44. Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice.
Brück J; Steitz J; Strand D; Tüting T
J Gene Med; 2005 May; 7(5):613-20. PubMed ID: 15580620
[TBL] [Abstract][Full Text] [Related]
45. [Anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Wei Y; Kan B
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):118-21. PubMed ID: 11783014
[TBL] [Abstract][Full Text] [Related]
46. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant.
Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS
Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911
[TBL] [Abstract][Full Text] [Related]
47. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
48. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
49. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses.
Smith SG; Patel PM; Porte J; Selby PJ; Jackson AM
Clin Cancer Res; 2001 Dec; 7(12):4253-61. PubMed ID: 11751527
[TBL] [Abstract][Full Text] [Related]
50. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines.
Nair SK; Boczkowski D; Snyder D; Gilboa E
Eur J Immunol; 1997 Mar; 27(3):589-97. PubMed ID: 9079797
[TBL] [Abstract][Full Text] [Related]
51. Immunization of retrovirus-transfected dendritic cells induces specific cytotoxic T lymphocytes for two distinct malarial peptides presented by Kd molecule.
Hetttihewa LM
Int Immunopharmacol; 2003 Oct; 3(10-11):1401-11. PubMed ID: 12946436
[TBL] [Abstract][Full Text] [Related]
52. Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells.
Pietra G; Mortarini R; Parmiani G; Anichini A
Cancer Res; 2001 Nov; 61(22):8218-26. PubMed ID: 11719453
[TBL] [Abstract][Full Text] [Related]
53. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
[TBL] [Abstract][Full Text] [Related]
54. Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ; Parkinson DR; Marincola F
J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431
[TBL] [Abstract][Full Text] [Related]
55. Specificity and efficacy of dendritic cell-based vaccination against tuberculosis with complex mycobacterial antigens in a mouse model.
Rubakova E; Petrovskaya S; Pichugin A; Khlebnikov V; McMurray D; Kondratieva E; Baturina I; Kondratieva T; Apt A
Tuberculosis (Edinb); 2007 Mar; 87(2):134-44. PubMed ID: 17011827
[TBL] [Abstract][Full Text] [Related]
56. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
57. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides.
Nair S; Wearsch PA; Mitchell DA; Wassenberg JJ; Gilboa E; Nicchitta CV
J Immunol; 1999 Jun; 162(11):6426-32. PubMed ID: 10352256
[TBL] [Abstract][Full Text] [Related]
58. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).
Parkhurst MR; Fitzgerald EB; Southwood S; Sette A; Rosenberg SA; Kawakami Y
Cancer Res; 1998 Nov; 58(21):4895-901. PubMed ID: 9809996
[TBL] [Abstract][Full Text] [Related]
59. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery.
Zhang Z; Tongchusak S; Mizukami Y; Kang YJ; Ioji T; Touma M; Reinhold B; Keskin DB; Reinherz EL; Sasada T
Biomaterials; 2011 May; 32(14):3666-78. PubMed ID: 21345488
[TBL] [Abstract][Full Text] [Related]
60. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice.
Tüting T; Gambotto A; DeLeo A; Lotze MT; Robbins PD; Storkus WJ
Cancer Gene Ther; 1999; 6(1):73-80. PubMed ID: 10078966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
